Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Mol Pharm. 2017 Mar 30;14(5):1450–1459. doi: 10.1021/acs.molpharmaceut.6b01178

Figure 3.

Figure 3

Stability of the FKFL linker in human serum. Peptide monomers/polymers (400 μM) were incubated in human serum, and peptide products were extracted and analyzed by MALDI-TOF MS. Spectra at 12 h are shown. (A, C) Peptide monomers (3437 Da) underwent low levels of cleavage at the FKFL linker to release FLAhxBIM, as indicated by the appearance of a 2980 Da peak. (B, D) In contrast, formulation into polymers prevented undesired cleavage of the FKFL linker by serum proteases.